Healthpeak Properties, Inc.DOCNYSE
Loading
Healthpeak Properties is a $11.6B healthcare REIT focused on three property types: lab/life science facilities (primarily South San Francisco, San Diego, Boston), medical office buildings (MOBs) adjacent to major hospital systems, and continuing care retirement communities (CCRCs). The company exited skilled nursing in 2021 to focus on higher-quality, lower-risk healthcare real estate with investment-grade tenant credit profiles.
Generates rental income from long-term leases (average 7-10 years for labs, 5-7 years for MOBs) with annual rent escalators of 2.5-3.5%. Lab properties command premium rents ($60-90 PSF triple-net in South San Francisco) due to specialized infrastructure (HVAC, power, lab benches) creating high tenant switching costs. MOBs benefit from physician stickiness to hospital affiliations. CCRCs generate revenue through entrance fees and monthly service fees, with operators bearing occupancy risk under RIDEA structure. Pricing power derives from supply constraints in key lab markets and healthcare demand demographics.
Same-store NOI growth rates in lab and MOB portfolios (target: 3-5% annually)
Lab leasing spreads and occupancy trends in South San Francisco and San Diego clusters
Development pipeline IRRs (typically 6-8% cash yields on cost) and lease-up progress
Cap rate compression/expansion in healthcare real estate transaction market
10-year Treasury yield movements affecting REIT valuation multiples and cost of capital
Medicare reimbursement cuts reducing physician practice profitability and ability to pay MOB rents
Shift to outpatient/home-based care reducing demand for traditional medical office space
Biotech funding cycles creating boom-bust demand for lab space, particularly if IPO/M&A markets remain closed
Oversupply risk in lab markets as competitors (Alexandria, BioMed) develop competing projects in same clusters
Alexandria Real Estate (ARE) dominates lab/life science with larger scale, better locations, and deeper tenant relationships
Welltower and Ventas compete directly in MOB and senior housing with similar or larger portfolios
Private equity capital competing for healthcare real estate acquisitions, compressing cap rates and returns
Debt/Equity of 1.39x and moderate leverage (estimated 5.5-6.5x Net Debt/EBITDA) limits financial flexibility in downturn
Development pipeline concentration risk if multiple projects deliver into weak leasing environment
Floating-rate debt exposure (~$500M-1B estimated) creates earnings volatility as SOFR fluctuates
low - Healthcare utilization is non-discretionary and driven by demographics (aging population) rather than GDP. Lab demand tied to venture capital funding for biotech, which is cyclical but less GDP-correlated. CCRC occupancy can soften in recessions as seniors delay moves, but existing residents provide stable cash flow.
High sensitivity to long-term rates. Rising 10-year Treasury yields compress REIT valuation multiples as dividend yields become less attractive versus bonds. Higher rates increase cost of capital for acquisitions and development, reducing accretive growth opportunities. Floating-rate debt exposure (~20-30% of total debt) increases interest expense when short rates rise. However, in-place leases with 2.5-3.5% annual escalators provide partial inflation hedge.
Minimal direct credit exposure - tenant base is investment-grade heavy (major health systems, large biotech/pharma). Lab tenants backed by venture capital can face funding challenges in tight credit markets, potentially impacting lease renewals. Development projects require construction financing, where credit market disruptions increase costs or delay projects.
dividend - Healthcare REITs attract income-focused investors seeking 4-5% dividend yields with modest growth (3-5% FFO CAGR). Defensive characteristics appeal to risk-averse investors during economic uncertainty. Some growth investors attracted to lab portfolio exposure to biotech innovation themes.
moderate - Healthcare REITs exhibit lower volatility than equity REITs overall (estimated beta 0.8-1.0) due to non-discretionary demand. However, interest rate sensitivity creates significant volatility during Fed policy shifts. Recent 18% one-year decline reflects rate sensitivity and biotech funding concerns.